Glaucoma implant could replace daily eye drops

NCT ID NCT07075718

Recruiting now Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a second-generation travoprost implant placed inside the eye to lower pressure in people with open-angle glaucoma or ocular hypertension. About 610 participants will receive either the implant, timolol eye drops, a sham procedure, or placebo drops. The main goal is to see if the implant safely reduces eye pressure over three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: travoprost implant
What this could lead to: If successful, this implant could offer a long-lasting way to lower eye pressure in glaucoma patients, reducing the need for daily eye drops.
What could go wrong: This is an early-to-mid stage trial, so the implant may not work as well as hoped or could cause side effects like eye irritation or vision changes. It is also compared to standard drops, so benefits over current care are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Glaukos Clinical Site
RECRUITING

El Paso, Texas, 79922, United States

Contact Email: •••••@•••••
Glaukos Investigative Site
RECRUITING

Grand Junction, Colorado, 81501, United States

Contact Email: •••••@•••••
Glaukos Investigative Site
RECRUITING

Oklahoma City, Oklahoma, 73112, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.